{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"acarbose\" outputclass=\"int-drug\">acarbose</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  acarbose  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acarbose</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"alogliptin\" outputclass=\"int-drug\">alogliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  alogliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alogliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  canagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">Clopidogrel</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Clopidogrel   increases   the exposure to   pioglitazone .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  dapagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">Deferasirox</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Deferasirox   is predicted to   increase   the exposure to   pioglitazone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"dulaglutide\" outputclass=\"int-drug\">dulaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  dulaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dulaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  empagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  ertugliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"exenatide\" outputclass=\"int-drug\">exenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  exenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Exenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fenfluramine\" outputclass=\"int-drug\">Fenfluramine</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">blood glucose concentrations when given with</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fenfluramine   might   decrease   blood glucose concentrations when given with   pioglitazone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenfluramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"gemfibrozil\" outputclass=\"int-drug\">Gemfibrozil</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Gemfibrozil   increases   the exposure to   pioglitazone .  Manufacturer advises monitor blood glucose and adjust dose .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemfibrozil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"glibenclamide\" outputclass=\"int-drug\">glibenclamide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  glibenclamide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glibenclamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"gliclazide\" outputclass=\"int-drug\">gliclazide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  gliclazide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gliclazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"glimepiride\" outputclass=\"int-drug\">glimepiride</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  glimepiride  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glimepiride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"glipizide\" outputclass=\"int-drug\">glipizide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  glipizide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glipizide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"insulin\" outputclass=\"int-drug\">insulin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  insulin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Insulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">Pioglitazone</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">isavuconazole</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Pioglitazone   potentially   decreases   the exposure to   isavuconazole .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">Leflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Leflunomide   is predicted to   increase   the exposure to   pioglitazone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"linagliptin\" outputclass=\"int-drug\">linagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  linagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"liraglutide\" outputclass=\"int-drug\">liraglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  liraglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Liraglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"lixisenatide\" outputclass=\"int-drug\">lixisenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  lixisenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lixisenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"metformin\" outputclass=\"int-drug\">metformin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  metformin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metformin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"mifepristone\" outputclass=\"int-drug\">Mifepristone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Mifepristone   is predicted to   increase   the exposure to   pioglitazone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifepristone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"opicapone\" outputclass=\"int-drug\">Opicapone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Opicapone   is predicted to   increase   the exposure to   pioglitazone .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Opicapone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"repaglinide\" outputclass=\"int-drug\">repaglinide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  repaglinide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Repaglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   moderately   decreases   the exposure to   pioglitazone .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"saxagliptin\" outputclass=\"int-drug\">saxagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  saxagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saxagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"semaglutide\" outputclass=\"int-drug\">semaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  semaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Semaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"sitagliptin\" outputclass=\"int-drug\">sitagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  sitagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sitagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   slightly   decreases   the exposure to   pioglitazone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">Teriflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Teriflunomide   is predicted to   increase   the exposure to   pioglitazone .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Teriflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"tolbutamide\" outputclass=\"int-drug\">tolbutamide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  tolbutamide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolbutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2#bnf_i1643858003535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"pioglitazone\" outputclass=\"int-heading-drug\">pioglitazone</ph> and <ph otherprops=\"vildagliptin\" outputclass=\"int-drug\">vildagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  pioglitazone  and  vildagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vildagliptin</title>"
					}
				}
			],
			"hasSearchLabel": " Pioglitazone  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/pioglitazone-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Pioglitazone </title>"
			},
			"rdfs:label": "pioglitazone"
		}
	]
}